CCL19 and cancer: CPSCs differentiated into CCL19+ TPSCs in immune‐enriched regions, MYH11+ TPSCs in the stromal region, and PLXDC1+ TPSCs, which exhibited cancer‐associated myofibroblasts (myCAFs) phenotype linked to poor prognosis.